Europe Expansion Napo operates under Jaguar Health and has an EU expansion vehicle (Napo Therapeutics S.p.A.) to broaden crofelemer access in Europe. This creates sales opportunities through licensing, distribution, or copromotion agreements with EU GI networks, pediatric centers, and national payers. Leverage the European focus to align regulatory, reimbursement, and clinical trial strategies.

Pediatric GI Focus Recent ESPGHAN participation and abstracts on pediatric intestinal disorders (MVID and SBS) signal strong pediatric market demand for non opioid GI therapies. Sales opportunities exist to partner with pediatric gastroenterology centers, hospitals, and key opinion leaders for trials, registries, and payer discussions. Coordinate outreach with the EU expansion plan to maximize cross-border collaborations.

Plant Based Advantage Plant derived, non opioid GI therapies position Napo with a differentiated value proposition in hospital formularies and payer negotiations. Opportunity to pitch crofelemer and future plant based assets to GI departments and integrated delivery networks seeking opioid sparing options. Consider codevelopment or licensing in markets prioritizing sustainable medicines and explore synergies with Magdalena Biosciences.

Access and Reimbursement Established patient support and reimbursement programs (NapoCares and iAssist) with AssistRx provide a ready path to payer engagement and faster access. Opportunity to expand these programs to European markets via Napo Therapeutics and to other chronic GI indications, hospitals, and IDNs. Develop payer specific value dossiers highlighting healthcare savings and the non opioid safety profile.

Mental Health Partnerships Magdalena Biosciences, a joint venture with Filament Health, focuses on natural prescription medicines for mental health including ADHD in adults, opening opportunities for codevelopment or co marketing collaborations in US and European markets. Potential business development moves include cross vertical partnerships to broaden the pipeline beyond GI and attract new investor interest. Leverage joint venture capabilities to accelerate market entry and expand distribution channels.